BiotechTube

Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

Conditions

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

Trial Timeline

Jun 24, 2026 → Sep 25, 2029

NCT ID
NCT07468071

About Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab

Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab is a phase 1/2 stage product being developed by Novartis for Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07468071. Target conditions include Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer were approved

Approved (5) Terminated (1) Active (14)
✅letrozoleJiangsu Hengrui MedicineApproved
✅FulvestrantAstraZenecaApproved
✅PazopanibNovartisApproved
✅LetrozoleNovartisApproved
✅Trastuzumab emtansineRocheApproved
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07468071Phase 1/2Recruiting

Competing Products

20 competing products in Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
Tadalafil + GemcitabineEli LillyPhase 1
29
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
enfortumab vedotin (EV)Astellas PharmaPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
ASP3082Astellas PharmaPhase 2
42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
31